SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT

                   PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                          Date of Report: May 25, 1999



                                 MEDIMMUNE, INC.
             (Exact name of registrant as specified in its charter)



                         Commission File Number: 0-19131




               Delaware                                 52-1555759
        (State of Incorporation)                     (I.R.S. Employer
           Identification No.)



              35 West Watkins Mill Road, Gaithersburg, MD 20878
              (Address of principal executive office (Zip Code)


      Registrant's telephone number, including area code (301) 417-0770


                No Exhibits are being filed with this report


CytoGam and RespiGam are  registered  trademarks of the Company and Synagis is a
trademark.

MEDIMMUNE, INC.
Current Report on Form 8-K

ITEM 5.  OTHER EVENTS

MedImmune, Inc. reported the information contained in the following press
release dated May 21, 1999:


FOR IMMEDIATE RELEASE

Contacts:
Mark E. Kaufmann                 Laureen Cassidy
Director, Planning and Analysis  Director, International
MedImmune, Inc.                  Communications
301-417-0770 x321                Abbott Laboratories
                                 847-938-7743
William C. Roberts
Investor and Media Relations
MedImmune, Inc.
301-417-0770 x358


http://www.medimmune.com
http://www.abbott.com


EUROPEAN COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS ADOPTS POSITIVE
OPINION ON SYNAGISTM FOR PREVENTION OF RSV

Abbott  Park,  IL and  Gaithersburg,  MD,  May 21,  1999 -- Abbott  Laboratories
(NYSE:ABT) and MedImmune,  Inc.  (Nasdaq:MEDI) today announced that the European
Union's  Committee  for  Proprietary  Medicinal  Products  (CPMP) has  adopted a
positive opinion on SynagisTM (palivizumab), a monoclonal antibody developed for
the  prevention  of  a  serious  lower   respiratory  tract  disease  caused  by
respiratory  syncytial  virus  (RSV).  RSV is the  most  common  cause  of lower
respiratory infections in infants and children worldwide.  The CPMP opinion will
now be considered by the European  Commission,  which will make a final decision
regarding the issue of a marketing authorization.

Synagis  will be the only  preventive  treatment  in Europe for RSV in pediatric
patients  under two years old who  suffer  from  lung  problems  due to  chronic
broncopulmonary  dysplasia (BPD) or prematurity  (less than or equal to 35 weeks
gestational age). Synagis is administered monthly during peak RSV season with an
intramuscular (IM) injection to pediatric patients at high risk from RSV.

During the peak season in Europe, more than 50 percent of  hospitalizations  due
to respiratory infections in children under two involve RSV.  Recommendation for
approval of Synagis is based on a large,  randomized  study  demonstrating  a 55
percent reduction in the incidence of  hospitalization  due to RSV infections in
high-risk pediatric patients.

"The positive  opinion is a major step forward in making  Synagis  available for
children at high risk for RSV, " said David Goffredo,  vice president,  European
operations, Abbott Laboratories.

The positive opinion follows approvals in several markets,  including Argentina,
Australia, Brazil, Colombia, Kuwait, Mexico and the United States.

In December 1997, Abbott  Laboratories and MedImmune,  Inc., formed an exclusive
worldwide marketing alliance to commercialize Synagis.  Abbott has the exclusive
right to market and distribute  Synagis outside the United States.  In the U.S.,
where Synagis was approved for marketing in June 1998, MedImmune and Abbott have
an agreement to co-promote the product.

Abbott Laboratories is a global,  diversified health care company devoted to the
discovery,   development,   manufacturing   and  marketing  of   pharmaceutical,
diagnostic, nutritional and hospital products. Abbott Laboratories is located in
Abbott Park,  Ill. The company employs 56,000 people and markets its products in
more than 130 countries.

MedImmune,  Inc.,  located in  Gaithersburg,  Md.,  is a  biotechnology  company
focused on developing and marketing products that address medical needs in areas
such as infectious disease,  transplantation medicine,  autoimmune disorders and
cancer.  MedImmune markets three products through its hospital-based sales force
and has five new product candidates in clinical trials.

This announcement may contain,  in addition to historical  information,  certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions.  Actual
results could differ materially from those currently  anticipated as a result of
a number  of  factors,  including  risks  and  uncertainties  discussed  in both
companies' filings with the U.S. Securities and Exchange Commission.

                                     ###




(REGISTRANT)      MEDIMMUNE, INC.




BY (SIGNATURE)    /s/ David M. Mott
(NAME AND TITLE)  David M. Mott, Vice Chairman and Chief Financial Officer
(DATE)            May 25, 1999
[{"type": "8-K", "sequence": "1", "description": "EUROPEAN COMMITTEE FOR PROPRIETARY MEDICINAL", "secsgml_size_bytes": 5367}]
{"company-data": {"conformed-name": "MEDIMMUNE INC /DE", "cik": "0000873591", "assigned-sic": "2836", "irs-number": "521555759", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14657", "film-number": "99633829"}, "business-address": {"street1": "35 W WATKINS MILL RD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878", "phone": "3014170770"}, "mail-address": {"street1": "35 W WATKINS MILL ROAD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878"}}
SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                   PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                          Date of Report: May 25, 1999

                                 MEDIMMUNE, INC.
             (Exact name of registrant as specified in its charter)

                         Commission File Number: 0-19131

               Delaware                                 52-1555759
        (State of Incorporation)                     (I.R.S. Employer
           Identification No.)

              35 West Watkins Mill Road, Gaithersburg, MD 20878
              (Address of principal executive office (Zip Code)

      Registrant's telephone number, including area code (301) 417-0770

                No Exhibits are being filed with this report

CytoGam and RespiGam are  registered  trademarks of the Company and Synagis is a
trademark.

MEDIMMUNE, INC.
Current Report on Form 8-K

ITEM 5.  OTHER EVENTS

MedImmune, Inc. reported the information contained in the following press
release dated May 21, 1999:

FOR IMMEDIATE RELEASE

Contacts:
Mark E. Kaufmann                 Laureen Cassidy
Director, Planning and Analysis  Director, International
MedImmune, Inc.                  Communications
301-417-0770 x321                Abbott Laboratories
                                 847-938-7743
William C. Roberts
Investor and Media Relations
MedImmune, Inc.
301-417-0770 x358

http://www.medimmune.com
http://www.abbott.com

EUROPEAN COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS ADOPTS POSITIVE
OPINION ON SYNAGISTM FOR PREVENTION OF RSV

Abbott  Park,  IL and  Gaithersburg,  MD,  May 21,  1999 -- Abbott  Laboratories
(NYSE:ABT) and MedImmune,  Inc.  (Nasdaq:MEDI) today announced that the European
Union's  Committee  for  Proprietary  Medicinal  Products  (CPMP) has  adopted a
positive opinion on SynagisTM (palivizumab), a monoclonal antibody developed for
the  prevention  of  a  serious  lower   respiratory  tract  disease  caused  by
respiratory  syncytial  virus  (RSV).  RSV is the  most  common  cause  of lower
respiratory infections in infants and children worldwide.  The CPMP opinion will
now be considered by the European  Commission,  which will make a final decision
regarding the issue of a marketing authorization.

Synagis  will be the only  preventive  treatment  in Europe for RSV in pediatric
patients  under two years old who  suffer  from  lung  problems  due to  chronic
broncopulmonary  dysplasia (BPD) or prematurity  (less than or equal to 35 weeks
gestational age). Synagis is administered monthly during peak RSV season with an
intramuscular (IM) injection to pediatric patients at high risk from RSV.

During the peak season in Europe, more than 50 percent of  hospitalizations  due
to respiratory infections in children under two involve RSV.  Recommendation for
approval of Synagis is based on a large,  randomized  study  demonstrating  a 55
percent reduction in the incidence of  hospitalization  due to RSV infections in
high-risk pediatric patients.

"The positive  opinion is a major step forward in making  Synagis  available for
children at high risk for RSV, " said David Goffredo,  vice president,  European
operations, Abbott Laboratories.

The positive opinion follows approvals in several markets,  including Argentina,
Australia, Brazil, Colombia, Kuwait, Mexico and the United States.

In December 1997, Abbott  Laboratories and MedImmune,  Inc., formed an exclusive
worldwide marketing alliance to commercialize Synagis.  Abbott has the exclusive
right to market and distribute  Synagis outside the United States.  In the U.S.,
where Synagis was approved for marketing in June 1998, MedImmune and Abbott have
an agreement to co-promote the product.

Abbott Laboratories is a global,  diversified health care company devoted to the
discovery,   development,   manufacturing   and  marketing  of   pharmaceutical,
diagnostic, nutritional and hospital products. Abbott Laboratories is located in
Abbott Park,  Ill. The company employs 56,000 people and markets its products in
more than 130 countries.

MedImmune,  Inc.,  located in  Gaithersburg,  Md.,  is a  biotechnology  company
focused on developing and marketing products that address medical needs in areas
such as infectious disease,  transplantation medicine,  autoimmune disorders and
cancer.  MedImmune markets three products through its hospital-based sales force
and has five new product candidates in clinical trials.

This announcement may contain,  in addition to historical  information,  certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions.  Actual
results could differ materially from those currently  anticipated as a result of
a number  of  factors,  including  risks  and  uncertainties  discussed  in both
companies' filings with the U.S. Securities and Exchange Commission.

                                     ###

(REGISTRANT)      MEDIMMUNE, INC.

BY (SIGNATURE)    /s/ David M. Mott
(NAME AND TITLE)  David M. Mott, Vice Chairman and Chief Financial Officer
(DATE)            May 25, 1999